An autosomal dominant mutation in
ACTG1 in the DFNA20/26 locus at 17q25-qter was identified in patients with hearing loss. A
Thr278
Ile mutation was identified in helix 9 of gamma-actin
protein, which is predicted to alter
protein structure. This study identified the first disease causing mutation in gamma-actin and underlies the importance of gamma-actin as structural elements of the inner ear hair cells. Since then, other
ACTG1 mutations have been linked to
nonsyndromic hearing loss, including
Met305
Thr. A missense mutation in
ACTG1 at
Ser155
Phe has also been identified in patients with
Baraitser-Winter syndrome, which is a developmental disorder characterized by congenital
ptosis, excessively-arched eyebrows,
hypertelorism, ocular
colobomata,
lissencephaly, short stature, seizures and hearing loss. Differential expression of
ACTG1 mRNA was also identified in patients with
Sporadic Amyotrophic Lateral Sclerosis, a devastating disease with unknown causality, using a sophisticated
bioinformatics approach employing
Affymetrix long-oligonucleotide BaFL methods.
Single nucleotide polymorphisms in
ACTG1 have been associated with
vincristine toxicity, which is part of the standard treatment regimen for childhood
acute lymphoblastic leukemia.
Neurotoxicity was more frequent in patients that were
ACTG1 Gly310
Ala mutation carriers, suggesting that this may play a role in patient outcomes from
vincristine treatment. == Interactions ==